Drug intelligence / Profile preview

RCP-2-3

Development stage: Preclinical
Administration: Oral

Overview

RCP-2-3 is a natural pectic polysaccharide derived from the unripe fruits of *Rubus chingii Hu.*. Structurally, it is composed of homogalacturonan (HG) and rhamnogalacturonan II (RG-II) domains. This polysaccharide has demonstrated efficacy in inhibiting intestinal lipid absorption, leading to a reduction in postprandial serum triglyceride accumulation and an increase in lipid excretion. Preclinical studies in mice have shown that RCP-2-3 can reduce weight gain and improve dyslipidemia, suggesting its potential application in both the food and pharmaceutical industries for managing obesity and related metabolic disorders.

Beyond the preview

Go deeper on RCP-2-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RCP-2-3.

Explore the full profile